Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Total Non-Current Liabilities: 2020-2024

Historic Total Non-Current Liabilities for UroGen Pharma (URGN) over the last 5 years, with Dec 2024 value amounting to $290.7 million.

  • UroGen Pharma's Total Non-Current Liabilities rose 8.57% to $296.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $296.7 million, marking a year-over-year increase of 8.57%. This contributed to the annual value of $290.7 million for FY2024, which is 20.97% up from last year.
  • Latest data reveals that UroGen Pharma reported Total Non-Current Liabilities of $290.7 million as of FY2024, which was up 20.97% from $240.3 million recorded in FY2023.
  • Over the past 5 years, UroGen Pharma's Total Non-Current Liabilities peaked at $290.7 million during FY2024, and registered a low of $22.9 million during FY2020.
  • Its 3-year average for Total Non-Current Liabilities is $251.0 million, with a median of $240.3 million in 2023.
  • Data for UroGen Pharma's Total Non-Current Liabilities shows a peak YoY surged of 373.08% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows UroGen Pharma's Total Non-Current Liabilities stood at $22.9 million in 2020, then spiked by 373.08% to $108.5 million in 2021, then soared by 104.59% to $222.0 million in 2022, then rose by 8.27% to $240.3 million in 2023, then climbed by 20.97% to $290.7 million in 2024.